Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Its about the data

This article was originally published in Scrip

Executive Summary

Long-suffering investors in Switzerland's Addex received a welcome boost when the company reported positive phase IIa results for its mGluR5 negative allosteric modulator, dipraglurant for Parkinson’s Disease (PD) (scripintelligence.com, 22 March 2012).  The Addex share price jumped over 80% on the announcement, reflecting the relief by many investors that the Addex platform for discovering allosteric modulators may come up with something after a few disappointments. 

You may also be interested in...



Stockwatch: The Pandemic – Where Generics Failed To Reign

If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.

Stockwatch: The Pandemic’s Effects On Big Pharma – A Year In

Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.

Stockwatch: Oncology Dynamics Underscore Roche And AstraZeneca’s Contrasting Fortunes

Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel